163 related articles for article (PubMed ID: 34514582)
1. Calreticulin Immunohistochemistry in Myeloproliferative Neoplasms - Evolution of a New Cost-Effective Diagnostic Tool: A Retrospective Study with Histological and Molecular Correlation.
Roy S; Manipadam MT; Balasubramanian P
Turk Patoloji Derg; 2022; 38(1):25-33. PubMed ID: 34514582
[TBL] [Abstract][Full Text] [Related]
2. Mutant specific anti calreticulin antibody (CAL2) immunohistochemistry as a screening test for calreticulin (CALR) mutation testing.
Rahman K; Chandra D; Singh MK; Gupta R; Sharma A; Paul P; Kumar S; Sharma S; Nityanand S
Int J Lab Hematol; 2020 Oct; 42(5):604-611. PubMed ID: 32463176
[TBL] [Abstract][Full Text] [Related]
3. Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms.
Trung NT; Quyen DT; Hoan NX; Giang DP; Trang TTH; Velavan TP; Bang MH; Song LH
BMC Med Genet; 2019 Jun; 20(1):115. PubMed ID: 31248375
[TBL] [Abstract][Full Text] [Related]
4. Calreticulin mutation specific CAL2 immunohistochemistry accurately identifies rare calreticulin mutations in myeloproliferative neoplasms.
Mózes R; Gángó A; Sulák A; Vida L; Reiniger L; Timár B; Krenács T; Alizadeh H; Masszi T; Gaál-Weisinger J; Demeter J; Csomor J; Matolcsy A; Kajtár B; Bödör C
Pathology; 2019 Apr; 51(3):301-307. PubMed ID: 30606612
[TBL] [Abstract][Full Text] [Related]
5. Conformation sensitive gel electrophoresis for the detection of calreticulin mutations in BCR-ABL1-negative myeloproliferative neoplasms.
Zakaria NA; Rosle NA; Siti Asmaa MJ; Aziee S; Haiyuni MY; Samat NA; Husin A; Hassan R; Ramli M; Mohamed Yusoff S; Ibrahim IK; Al-Jamal HAN; Johan MF
Int J Lab Hematol; 2021 Dec; 43(6):1451-1457. PubMed ID: 34125992
[TBL] [Abstract][Full Text] [Related]
6. Calreticulin exon 9 mutations in myeloproliferative neoplasms.
Ha JS; Kim YK
Ann Lab Med; 2015 Jan; 35(1):22-7. PubMed ID: 25553276
[TBL] [Abstract][Full Text] [Related]
7. Megakaryocytes, erythropoietic and granulopoietic cells express CAL2 antibody in myeloproliferative neoplasms carrying CALR gene mutations.
Ali H; Puccio I; Akarca AU; Bob R; Pomplun S; Keong Wong W; Gupta R; Sekhar M; Lambert J; Al-Masri H; Stein H; Marafioti T
Int J Exp Pathol; 2021 Feb; 102(1):45-50. PubMed ID: 32929772
[TBL] [Abstract][Full Text] [Related]
8. Mutation Profile in BCR-ABL1-Negative Myeloproliferative Neoplasms: A Single-Center Experience From India.
Maddali M; Kulkarni UP; Ravindra N; Arunachalam AK; Venkatraman A; Lionel S; Manipadam MT; Devasia AJ; Korula A; Fouzia NA; Abraham A; Srivastava A; George B; Balasubramanian P; Mathews V
Hematol Oncol Stem Cell Ther; 2022 Jun; 15(2):13-20. PubMed ID: 33789164
[TBL] [Abstract][Full Text] [Related]
9. CAL2 Immunohistochemical Staining Accurately Identifies CALR Mutations in Myeloproliferative Neoplasms.
Nomani L; Bodo J; Zhao X; Durkin L; Loghavi S; Hsi ED
Am J Clin Pathol; 2016 Oct; 146(4):431-8. PubMed ID: 27686170
[TBL] [Abstract][Full Text] [Related]
10. Mutation specific immunohistochemistry is highly specific for the presence of calreticulin mutations in myeloproliferative neoplasms.
Andrici J; Farzin M; Clarkson A; Sioson L; Sheen A; Watson N; Toon CW; Koleth M; Stevenson W; Gill AJ
Pathology; 2016 Jun; 48(4):319-24. PubMed ID: 27114372
[TBL] [Abstract][Full Text] [Related]
11. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
Ahmed RZ; Rashid M; Ahmed N; Nadeem M; Shamsi TS
Asian Pac J Cancer Prev; 2016; 17(3):923-6. PubMed ID: 27039813
[TBL] [Abstract][Full Text] [Related]
12. A new monoclonal antibody (CAL2) detects CALRETICULIN mutations in formalin-fixed and paraffin-embedded bone marrow biopsies.
Stein H; Bob R; Dürkop H; Erck C; Kämpfe D; Kvasnicka HM; Martens H; Roth A; Streubel A
Leukemia; 2016 Jan; 30(1):131-5. PubMed ID: 26202929
[TBL] [Abstract][Full Text] [Related]
13. CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.
Ojeda MJ; Bragós IM; Calvo KL; Williams GM; Carbonell MM; Pratti AF
Hematology; 2018 May; 23(4):208-211. PubMed ID: 28990497
[TBL] [Abstract][Full Text] [Related]
14. Calreticulin Mutation by Immunohistochemistry: Can It Replace PCR?
Gupta A; Sazawal S; Mahapatra M; Pati HP; Saxena R
Appl Immunohistochem Mol Morphol; 2020 Sep; 28(8):621-626. PubMed ID: 31478923
[TBL] [Abstract][Full Text] [Related]
15. WHO-histological criteria for myeloproliferative neoplasms: reproducibility, diagnostic accuracy and correlation with gene mutations and clinical outcomes.
Alvarez-Larrán A; Ancochea A; García M; Climent F; García-Pallarols F; Angona A; Senín A; Barranco C; Martínez-Avilés L; Serrano S; Bellosillo B; Besses C
Br J Haematol; 2014 Sep; 166(6):911-9. PubMed ID: 24957246
[TBL] [Abstract][Full Text] [Related]
16. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
17. The Calreticulin gene and myeloproliferative neoplasms.
Clinton A; McMullin MF
J Clin Pathol; 2016 Oct; 69(10):841-5. PubMed ID: 27354406
[TBL] [Abstract][Full Text] [Related]
18. The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
Wu Z; Zhang X; Xu X; Chen Y; Hu T; Kang Z; Li S; Wang H; Liu W; Ma X; Guan M
J Hematol Oncol; 2014 Jul; 7():48. PubMed ID: 25023898
[TBL] [Abstract][Full Text] [Related]
19. The different variant allele frequencies of type I/type II mutations and the distinct molecular landscapes in
Pan Y; Wang X; Wen S; Liu X; Yang L; Luo J
Hematology; 2022 Dec; 27(1):902-908. PubMed ID: 36000955
[TBL] [Abstract][Full Text] [Related]
20. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms.
Tefferi A; Thiele J; Vannucchi AM; Barbui T
Leukemia; 2014 Jul; 28(7):1407-13. PubMed ID: 24441292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
